Cytotoxicity of allitinib, an irreversible anti-EGFR agent, in a large panel of human cancer-derived cell lines: KRAS mutation status as a predictive biomarker
Conclusions
The current study represents the largest in vitro assessment of allitinib cytotoxicity performed to date. Through this study, we identified cancer types that could potentially benefit from this drug. Additionally, our findings suggest that prevalent KRAS mutations constitute potential predictive biomarkers for allitinib response.
Source: Cellular Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Esophagus Cancer | Genetics | Head and Neck Cancer | Lung Cancer | Melanoma | Skin Cancer | Study